This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for China Pharma Holding's Median PS Value or its related term are showing as below:
CPHI'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16 Med: 1 Max: 3.48
Current: 0.18
During the past 13 years, the highest Price to Median PS Value of China Pharma Holding was 3.48. The lowest was 0.16. And the median was 1.00.
CPHI's Price-to-Median-PS-Value is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.86
vs CPHI: 0.18
China Pharma Holding Median PS Value Historical Data
The historical data trend for China Pharma Holding's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of China Pharma Holding's Median PS Value
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.7356.
China Pharma Holding's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.651.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (OTCPK:CPHI) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
China Pharma Holding's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.345
/
1.95
=
0.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding Median PS Value Related Terms
Thank you for viewing the detailed overview of China Pharma Holding's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
China Pharma Holding (China Pharma Holding) Business Description
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPHI has been successfully added to your 